Clinical Trials
33 trialsPembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
Neumedicines Inc.
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Dana-Farber Cancer Institute
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy
Neumedicines Inc.
Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer
Alliance for Clinical Trials in Oncology
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
University of Southern California
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
University of Southern California
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
University of Chicago
Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation
National Cancer Institute (NCI)
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
University of Chicago
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
National Cancer Institute (NCI)
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
National Cancer Institute (NCI)
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
National Cancer Institute (NCI)
Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer
NYU Langone Health
Interleukin-12 in Treating Patients With Cancer in the Abdomen
M.D. Anderson Cancer Center
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Mayo Clinic